Interferon Î²-1a decreased the risk for conversion to clinically definite/multiple sclerosis
- news. // Inside MS;Oct-Dec2002, Vol. 20 Issue 4, p25
Presents an update on issues concerning multiple sclerosis in the U.S. as of October 2002. Medicare coverage for Avonex interferon drug; Findings of a study on interferon; Highlights of a meeting held by the American Academy of Neurology.
- Blockade of gamma interferon might be beneficial in MS. Steinman, L. // Multiple Sclerosis (13524585);Oct2001, Vol. 7 Issue 5, p275
Comments on the application of the blockade of gamma interferon in the treatment of multiple sclerosis. Clinical trial of copaxone; Tests conducted on other antibody treatment; Failure in the trial of anti-tumor necrosis factor approach.
- International consensus statement on the use of disease-modifying agents in multiple sclerosis. Freedman, M S; Blumhardt, L D; Brochet, B; Comi, G; Noseworthy, J H; Sandberg-Wollheim, M; Soelberg S�rensen, P // Multiple Sclerosis (13524585);Feb2002, Vol. 8 Issue 1, p19
Objective: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods: An initial draft of the consensus statement was prepared by the Steering Committee...
- Depression in Multiple Sclerosis Associated with Interferon Beta-1a (Rebif). Pandya, Rupang; Patten, Scott // Canadian Journal of Psychiatry;Sep2002, Vol. 47 Issue 7, p686
Examines the case of depression in multiple sclerosis (MS) associated with interferon Beta-1a. Diagnosis of a 42 year old Caucasian woman with relapsing and remitting MS; History of bulimia during teenage; Effective treatment of paroxetine with interferon alfa-2b.
- Interferon-ï¿½ dose and efficacy: the OPTIMS study. Durelli, L.; Oggero, A.; Verdun, E.; Barbero, P.; Pipieri, A.; Isoardo, G.; Ricci, A.; Clerico, M.; Bradac, G.; Bergamasco, B.; Bergui, M. // Neurological Sciences;Apr2001, Vol. 22 Issue 2, p201
Interferon beta (IFN-ï¿½) reduces exacerbation rates in patients with relapsing-remitting multiple sclerosis (MS), but some patients do not respond to treatment. Recent studies have shown a clear dose-response effect on the reduction of exacerbation rates, and on burden of disease...
- Implication of the Toll-like receptor 4 pathway in the response to interferon-ï¿½ in multiple sclerosis. // Current Medical Literature: Multiple Sclerosis;2012, Vol. 4 Issue 1, p19
An abstract of the article "Implication of the Toll-like receptor 4 pathway in the response to interferon-ï¿½ in multiple sclerosis," by M. F. Bustamante, and colleagues is presented.
- Interferon Beta May Not Reduce Disability Progression for Patients With MS. // Neurology Reviews;Aug2012, Vol. 20 Issue 8, p22
The article presents information on study according to which treatment with interferon beta medicine was not associated with reduced progression of disability in relapsing-remitting multiple sclerosis patients.
- Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. Dubois, B.D.; Keenan, E.; Porter, B.E.; Kapoor, R.; Rudge, P.; Thompson, A.J.; Miller, D.H.; Giovannoni, G. // Journal of Neurology, Neurosurgery & Psychiatry;Jul2003, Vol. 74 Issue 7, p946
Background: The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting multiple sclerosis (MS). However, the use of this drug in clinical practice is complex, especially because it is only partially effective, its long term efficacy and side effects are unknown, its...
- Recombinant Interferon-Î²-1a: A Review of its Therapeutic Efficacy in Relapsing-Remitting Multiple Sclerosis. Wagstaff, A.J.; Goa, K.L. // BioDrugs;1998, Vol. 10 Issue 6, p471
This review focuses on Rebif, one of 2 available formulations of recombinant interferon-Î²-1a, a molecule with the same molecular weight and primary structure as native interferon-Î². The product under review is intended for subcutaneous injection and contains 22 or 44Âµg of recombinant...
- Treatment of Multiple Sclerosis with the Interferon-Î²s: Comparative Risks and Benefits. Herndon, R.M. // BioDrugs;1998, Vol. 10 Issue 6, p463
Several inteferons (IFNs) have recently been introduced for the treatment of multiple sclerosis (MS). These are IFNÎ²-1b (Betaseron) and 2 IFNÎ²-1a preparations (Avonex and Rebif). All 3 drugs reduce the number of acute exacerbations in relapsing remitting MS by about one-third but, because...